Prevalence, Psychiatrist Intervention
Conditions
Keywords
Randomized control trial, Charles Bonnet syndrome, visual hallucinations, age related macular degeneration, patient education
Brief summary
Charles Bonnet Syndrome (CBS) is defined by the occurence of visual hallucinations (VH) in the absence of any mental disorder. Elderly patients with reduced visual acuity due to ophthalmic diseases are most affected. Conditions are often associated with the syndrome of age-related macular degeneration, cataract or glaucoma. Existing data on the syndrome's prevalence in Europe reveal diverse results. Aim of this study was to assess the prevalence of CBS in patients with low visual acuity and to evaluate, if an additional therapeutic interview with and treatment by a psychiatrist is beneficial.
Detailed description
Patients with a visual acuity of 0.5 LogMAR or less in the better eye were screened for CBS. Instruments used were an interview asking for details of the hallucinations, a mental test and a scale concerning quality of life. Patients with CBS were randomized by minimization in two groups: in group 1, a patient-doctor interview by an ophthalmologist was performed and in group 2 an interview and if needed, a therapy by a psychiatrist. At the 3-months follow up, the psychological strain of patients was recorded again.
Interventions
control group: interview, study group: explanation and exploration
Sponsors
Study design
Eligibility
Inclusion criteria
* written informed consent * visual acuity of 0.5 LogMAR or less at both eyes * 55 years or older Patients with CBS: * have no mental pathologies such as dementia, psychosis or any other neurological diseases * have a normal cognitive state * are not able to control the VH * know that the VH are not real * are usually older * have significantly reduced visual acuity due to an bilateral eye pathology VH associated with CBS: * disappear when the eyes are closed * are repetitive * are complex (eg. objects, geometrical patterns, faces, shapes, figures, scenes, animals or plants)
Exclusion criteria
* dopamine agonist medication * temporal lobe epilepsy * moderate to severe Alzheimer's dementia * present chronic alcohol-/drug abuse * bad cognitive state There are no: * auditory or olfactory hallucinations * other abnormalities like delusions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quality of life score between the two groups | 3 months | Quality of life score between the study and control group |